三氧化二砷对鼻咽癌放射增敏的近期疗效  

Short-term Effect of Arsenic trioxide on Radiosensitivity in the Patients with Nasopharyngeal Carcinoma

作　　者：陈创珍[1] 李德锐[1] 陈志坚[1] 林英城[1] 周明镇[1] 郭隆佳[1] 郭竑[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院,广东汕头515031

出　　处：《肿瘤学杂志》2008年第12期992-995,共4页Journal of Chinese Oncology

基　　金：国家中医药管理局中医药科学技术研究专项基金资助项目(04-05LL10);广东省科技攻关基金资助项目(2004B30301014);广东省中医药管理局科研立项资助项目(102053)

摘　　要：[目的]探讨三氧化二砷对鼻咽癌放射增敏作用。[方法]87例T1～4N0～1期鼻咽癌病人随机分为单纯放疗组(对照组)和三氧化二砷+放射治疗组(试验组),观察两组病人鼻咽肿瘤和颈部肿瘤消退情况,1、2年生存率及毒副反应。[结果]放射治疗40Gy时试验组和对照组的鼻咽肿瘤消退率分别为45.45%(20/44)和18.60%(8/43),差异有统计学意义(χ2=7.183,P=0.007)。两组的颈部肿瘤消退速度无统计学差异。40Gy时肿瘤消失组和残留组1、2年无病生存率分别为100%、90.9%和82.2%、69.3%,差异有统计学意义。试验组白细胞降低和恶心呕吐较对照组发生率高,但多为Ⅰ～Ⅱ度反应。其他毒副反应两组间差异无统计学意义。[结论]放疗联合三氧化二砷增敏使鼻咽肿瘤消退更快,且无严重毒副作用。[Purpose] To evaluate the radiosensitizing effect of arsenic trioxide （ATO） on nasopharyngeal carcinoma（NPC）. [Methods] Eighty-seven patients with NPC T1-4N0-1M0 were randomized into two groups： conventional fractionation radiotherapy group （control group） and conventional fractionation radiotherapy plus ATO group（study group）. The regressions of nasopharyngeal lesions and cervical lymph nodes, as well as the 1-year and 2-year survival rates and acute toxicities were compared between two groups. [ Results ] When irradiation dose reached 40Gy, the completely regression rates of primary nasopharyngeal lesion were 18.60%（8/43）in control group and 45.45% （20/44） in study group with statistical significance （X^2=7.183,P=0.007）. The 1-year and 2-year survival rate was higher in patients with CR than that in those with residual disease at the time of 40Gy delivered （100% vs 82.2% and 90.9% vs 69.3%） with statistical significance （X^2=4.481,P= 0.034）. Toxicities in the two groups were not different except of nausea, vomiting and granulocytopenia, those were more frequent in study group. Most patients experienced grade 1 to 2 acute toxicities in both groups. [Conclusionl ATO combined with radiotherapy may accelerate tumor regression in nasopharyngeal carcinoma without severe toxicities.

关 键 词：鼻咽肿瘤 三氧化二砷 放射疗法 放射增敏 

分 类 号：R730.55[医药卫生—肿瘤] R739.63[医药卫生—临床医学]